Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Prediction of AD dementia… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.

Artikel i vetenskaplig tidskrift
Författare Annapaola Prestia
Anna Caroli
Sara K Wade
Wiesjie M van der Flier
Rik Ossenkoppele
Bart Van Berckel
Frederik Barkhof
Charlotte E Teunissen
Anders Wall
Stephen F Carter
Michael Schöll
Il Han Choo
Agneta Nordberg
Philip Scheltens
Giovanni B Frisoni
Publicerad i Alzheimer's & dementia : the journal of the Alzheimer's Association
Volym 11
Nummer/häfte 10
Sidor 1191-201
ISSN 1552-5279
Publiceringsår 2015
Publicerad vid
Sidor 1191-201
Språk en
Länkar dx.doi.org/10.1016/j.jalz.2014.12.0...
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Aged, Aged, 80 and over, Alzheimer Disease, diagnosis, Amyloid beta-Peptides, cerebrospinal fluid, Amyloidosis, Atrophy, Biomarkers, cerebrospinal fluid, Disease Progression, Fluorodeoxyglucose F18, Hippocampus, pathology, Humans, Male, Middle Aged, Positron-Emission Tomography, Predictive Value of Tests, Prognosis, Sensitivity and Specificity, tau Proteins, cerebrospinal fluid
Ämneskategorier Medicinsk bioteknologi, Klinisk medicin

Sammanfattning

Proposed diagnostic criteria (international working group and National Institute on Aging and Alzheimer's Association) for Alzheimer's disease (AD) include markers of amyloidosis (abnormal cerebrospinal fluid [CSF] amyloid beta [Aβ]42) and neurodegeneration (hippocampal atrophy, temporo-parietal hypometabolism on [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET), and abnormal CSF tau). We aim to compare the accuracy of these biomarkers, individually and in combination, in predicting AD among mild cognitive impairment (MCI) patients.In 73 MCI patients, followed to ascertain AD progression, markers were measured. Sensitivity and specificity, positive (LR+) and negative (LR-) likelihood ratios, and crude and adjusted hazard ratios were computed.Twenty-nine MCI patients progressed and 44 remained stable. Positivity to any marker achieved the lowest LR- (0.0), whereas the combination Aβ42 plus FDG-PET achieved the highest LR+ (6.45). In a survival analysis, positivity to any marker was associated with 100% conversion rate, whereas negativity to all markers was associated with 100% stability.The best criteria combined amyloidosis and neurodegeneration biomarkers, whereas the individual biomarker with the best performance was FDG-PET.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?